Unfortunately, bortezomib was ineffective in controlling metastatic CRC disease, but a significant accumulation of HIF-1α was seen in tumor specimens and xenograft models, suggesting that proteasome inhibition could alter the response to tumor hypoxia [124]. This evidence concerns the gene HIF1A and neoplasm.